Skip to main content

Advertisement

Table 5 Association between breast cancer and various cumulative PCE exposure

From: Risk of breast cancer following exposure to tetrachloroethylene-contaminated drinking water in Cape Cod, Massachusetts: reanalysis of a case-control study using a modified exposure assessment

Prior Analysis
  PCE EXPOSURE LEVEL
Latency period (years) ≤Median >Median >75th Percentile >90th Percentile
0     
Case/control 91/109 100/108 59/54 18/21
COR (95% CI) 1.2 (0.9-1.6) 1.4 (1.0-1.8) 1.6 (1.1-2.3) 1.3 (0.7-2.4)
AOR (95% CI) 1.0 (0.7-1.3) 1.2 (0.9-1.7) 1.6 (1.1-2.4) 1.3 (0.7-2.6)
5     
Case/control 79/82 75/81 50/40 17/16
COR (95% CI) 1.4 (1.0-2.0) 1.4 (1.0-1.9) 1.8 (1.2-2.8) 1.6 (0.8-3.1)
AOR (95% CI) 1.1 (0.8-1.5) 1.3 (0.9-1.8) 1.6 (1.0-2.6) 1.5 (0.7-3.0)
7     
Case/control 59/68 69/67 46/33 17/13
COR (95% CI) 1.3 (0.9-1.8) 1.5 (1.1-2.1) 2.0 (1.3-3.2) 1.9 (0.9-4.0)
AOR (95% CI) 0.9 (0.6-1.3) 1.3 (0.9-1.9) 1.8 (1.1-2.9) 1.7 (0.8-3.6)
9     
Case/control 48/55 63/55 40/27 16/11
COR (95% CI) 1.3 (0.9-1.9) 1.7 (1.2-2.4) 2.2 (1.3-3.6) 2.1 (1.0-4.6)
AOR (95% CI) 0.9 (0.6-1.4) 1.4 (0.9-2.0) 1.9 (1.1-3.2) 1.9 (0.8-4.4)
11     
Case/control 39/42 47/41 29/20 12/8
COR (95% CI) 1.4 (0.9-2.1) 1.7 (1.1-2.6) 2.1 (1.2-3.8) 2.2 (0.9-5.4)
AOR (95% CI) 1.0 (0.6-1.5) 1.4 (0.9-2.1) 1.8 (1.0-3.3) 1.8 (0.7-4.8)
13     
Case/control 35/26 30/26 17/13 8/5
COR (95% CI) 2.0 (1.2-3.3) 1.7 (1.0-2.9) 1.9 (0.9-4.0) 2.3 (0.8-7.2)
AOR (95% CI) 1.4 (0.8-2.3) 1.3 (0.8-2.3) 1.6 (0.7-3.5) 1.7 (0.5-5.2)
15     
Case/control 26/18 18/17 12/8 2/3
COR (95% CI) 2.1 (1.2-3.9) 1.6 (0.8-3.0) 2.2 (0.9-5.4) 1.0 (0.2-5.9)
AOR (95% CI) 1.5 (0.8-2.8) 1.1 (0.6-2.3) 1.7 (0.7-4.3) -
17     
Case/control 11/11 10/10 4/5 1/2
COR (95% CI) 1.5 (0.6-3.4) 1.5 (0.6-3.5) 1.2 (0.3-4.4) 0.7 (0.1-8.1)
AOR (95% CI) 1.0 (0.4-2.4) 1.0 (0.4-2.6) 0.9 (0.2-3.4) -
19     
Case/control 6/5 3/4 2/2 0/0
COR (95% CI) 1.8 (0.5-5.8) 1.1 (0.2-4.9) 1.5 (0.2-10.4) -
AOR (95% CI) 1.3 (0.4-4.2) 0.9 (0.2-4.1) - -
Current analysis
  PCE EXPOSURE LEVEL
Latency period (years) < Median >Median >75th Percentile >90th Percentile
0     
Case/control 224/324 225/324 123/162 56/64
COR (95% CI) 1.0 (0.8-1.2) 1.0 (0.8-1.2) 1.1 (0.8-1.4) 1.2 (0.8-1.8)
AOR (95% CI) 0.9 (0.8-1.2) 1.0 (0.8-1.3) 1.1 (0.9-1.5) 1.3 (0.9-1.9)
5     
Case/control 193/276 206/276 104/138 53/55
COR (95% CI) 1.0 (0.8-1.2) 1.0 (0.8-1.3) 1.0 (0.8-1.4) 1.3 (0.9-2.0)
AOR (95% CI) 0.9 (0.7-1.2) 1.1 (0.9-1.4) 1.1 (0.8-1.5) 1.4 (0.9-2.1)
7     
Case/control 176/248 189/248 101/124 51/49
COR (95% CI) 1.0 (0.8-1.3) 1.0 (0.8-1.3) 1.1 (0.8-1.5) 1.5 (1.0-2.2)
AOR (95% CI) 1.0 (0.8-1.3) 1.1 (0.9-1.4) 1.1 (0.8-1.5) 1.4 (0.9-2.2)
9     
Case/control 148/218 171/218 89/109 47/43
COR (95% CI) 1.0 (0.7-1.2) 1.1 (0.9-1.4) 1.1 (0.8-1.5) 1.5 (1.0-2.4)
AOR (95% CI) 1.0 (0.7-1.2) 1.1 (0.8-1.3) 1.1 (0.8-1.5) 1.4 (0.9-2.2)
11     
Case/control 122/188 159/188 75/94 40/37
COR (95% CI) 0.9 (0.7-1.2) 1.2 (0.9-1.5) 1.1 (0.8-1.5) 1.5 (1.0-2.5)
AOR (95% CI) 0.9 (0.7-1.2) 1.1 (0.8-1.4) 1.0 (0.7-1.4) 1.4 (0.9-2.4)
13     
Case/control 106/163 136/162 73/81 37/32
COR (95% CI) 0.9 (0.7-1.2) 1.2 (0.9-1.5) 1.2 (0.9-1.7) 1.7 (1.0-2.7)
AOR (95% CI) 0.9 (0.7-1.2) 1.0 (0.8-1.4) 1.1 (0.8-1.6) 1.5 (0.9-2.5)
15     
Case/control 85/115 101/114 50/57 20/22
COR (95% CI) 1.0 (0.8-1.4) 1.2 (0.9-1.6) 1.2 (0.8-1.8) 1.3 (0.7-2.4)
AOR (95% CI) 1.0 (0.7-1.3) 1.0 (0.7-1.3) 1.0 (0.7-1.5) 1.0 (0.5-1.9)
17     
Case/control 61/71 69/70 31/35 18/14
COR (95% CI) 1.2 (0.8-1.7) 1.3 (0.9-1.9) 1.2 (0.7-2.0) 1.7 (0.8-3.5)
AOR (95% CI) 0.9 (0.6-1.3) 1.0 (0.7-1.5) 0.9 (0.5-1.5) 1.3 (0.6-2.7)
19     
Case/control 34/40 50/38 19/19 9/7
COR (95% CI) 1.1 (0.7-1.8) 1.8 (1.1-2.7) 1.3 (0.7-2.6) 1.7 (0.6-4.7)
AOR (95% CI) 0.8 (0.5-1.3) 1.3 (0.8-2.0) 1.0 (0.5-2.0) 1.3 (0.5-3.6)
  1. Note: Referent group in the prior analysis was comprised of never exposed cases (n = 739) and controls (n = 1,085). The referent group in the current analysis was comprised of never exposed cases (n = 471) and controls (n = 645). Both adjusted analyses controlled for age at diagnosis or index year, vital status at interview, family history of breast cancer, personal history of breast cancer (before current diagnosis or index year), age at first live birth or stillbirth, occupational exposure to PCE, and study of origin.